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Abstract
Background: The facts that LPA is present at high concentration in ovarian cancer patients’ ascites and it may
serve as a stimulator to cell migration, implicate the role of LPA in the ovarian cancer metastasis. Since LPA
mediates various biological functions through its interaction with LPA receptors, we aim to investigate the
correlation between the expression of LPA receptors and the metastasis of ovarian cancer.
Methods: To test whether the LPA responsiveness correlated with the metastatic capability of ovarian cancer cells,
we performed LPA induced invasion assay and peritoneal metastatic colonization assay with a panel of established
human ovarian cancer cell lines. The expression of LPAR1-3 in different ovarian cancer lines was examined by
qRT-PCR. We also tested the effects of LPAR1 inhibition or overexpression on ovarian cancer cell's invasiveness.
To confirm our laboratory results, we detected LPARs expression in specimens from 52 ovarian cancer patients by
qRT-PCR and immunohistochemistry.
Results: Thirteen ovarian cancer cells were enrolled in the invasion assay. Ovarian cancer cell lines which
responded well to LPA-induced invasion, also displayed good capability for metastatic colonization. On the
contrary, cell lines with poor LPA responsiveness showed inferior metastatic potential in peritoneal colonization
assay. High expression level of LPAR1 was detected in all of the metastatic ovarian cancer cell lines. T-test showed
that LPAR1, not LPAR2 or LPAR3, expression was significantly higher in the metastatic cell lines than in the non-
metastatic cell lines (P = 0.003). Furthermore, silencing LPAR1 alone could significantly reduce LPA-induced invasion
(P < 0.001). Finally, we analyzed the correlation between the LPARs expression and clinicopathological features of
the clinical cases. It indicated that LPAR1 expression rate increased significantly along with the more advanced
stages (stage I: 16.67 %; II 50.00 %; III: 75.00 %; and IV: 100.00 %; P = 0.003). Besides that, LPAR1 expression was
detected in all the 13 cases with abdominal metastasis more than 2 cm, 10 cases with retroperitoneal lymph node
metastasis and 6 cases with hepatic metastasis. Moreover, the expression rate of LPAR2 significantly increased in
ovarian cancer than in normal specimens (P = 0.039). LPAR3 expression showed the same trend as LPAR2, though
the difference is not statistically significant (P = 0.275). Besides that LPAR2 and LPAR3 expression increased along
with poorer differentiation (P = 0.002, P = 0.034, respectively).
Conclusions: Metastatic capability of ovarian cancer cells correlated well with their responsiveness to LPA for cell
invasion. LPAR1 acts as the main mediator responsible for LPA-stimulated ovarian cancer cell invasion. LPAR2 and
LPAR3 might play an role in carcinogenesis of ovarian cancer.
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Background
Ovarian cancer is the most lethal disease among all the
gynecological cancers. The high mortality rate of ovarian
cancer is mainly due to the complications of metastasis. Once
the epithelial cells covering the ovaries undergo neoplastic
transformation, they exfoliate from the primary tumor and
disseminate to the peritoneal cavity through implantation
pattern. It is widely recognized that the accumulation of
malignant ascites is one of the most typical behaviors of
ovarian cancers and may help the cancer cells to seed the
abdominal cavity organs with tumor implants [1].
Lysophosphatic acid (LPA) is a growth factor-like
phospholipid that elicits multiple cellular events, including
cell migration, proliferation, and survival [2, 3]. LPA is
uniquely associated with ovarian malignancies, as signified
by its presence at high concentrations in the ascites of
ovarian cancer patients [4, 5], and its production and
secretion into the peritoneal cavity by ovarian cancer cells
[6, 7] as well as mesothelial cells [8]. Moreover, LPA stim-
ulates ovarian cancer cell migration [9, 10], triggers prote-
ase production/activation in ovarian cancer cells [11, 12],
induces Cox-2 expression [13], and facilitates angiogenesis
through the induction of various proangiogenic factors,
such as VEGF [14], IL8 [15], and Groα [16]. These find-
ings implicate the role of peritoneal fluid- or ascites-borne
LPA as a potent promoter of peritoneal metastasis of ovar-
ian cancer. The cellular responses of LPA are mediated by
a group of G protein-coupled receptors (GPCRs), in which
LPAR1, LPAR2, and LPAR3 are best characterized and
widely expressed [17, 18]. Previous reports have suggested
that an upregulated expression of LPAR may be involved
in the mechanism underlying tumor growth and metasta-
sis [19, 20]. However, a few studies have focused on the
correlation between LPA receptors and ovarian cancers.
It has been long recognized that the ability of cancer
cells to invade the surrounding tissues is essential for
metastasis. The facts that the levels of LPA are elevated in
the ascites in ovarian cancer patients, and that LPA may
serve as a stimulator to cell migration as well as protease
production/activation, prompted us to hypothesize that
LPA-stimulated cancer cell invasion may play a critical
role in ovarian cancer metastasis. Here, we presented that
the peritoneal metastatic colonization of ovarian cancer
cells is associated with their ability to respond to LPA for
cell invasion. Besides, we demonstrated that LPAR1 acts
as the main mediator responsible for LPA-stimulated
ovarian cancer cell invasion. LPAR2 and LPAR3 might
play an role in carcinogenesis of ovarian cancer.
Methods
Cells and antibodies
The human ovarian cancer cell lines, ES2, OVCAR429,
HEY, OVCAR433, OVCAR5, SK-OV3, OCC1, OVCAR3,
TOV21G, HEC1A, IGROV1, A2780, and OVCAR4 were
provided by the Department of Biochemistry and Mo-
lecular Biology, Georgia Regents University (Georgia,
USA) as a kind gift. Cells were cultured in Dulbecco's
modified Eagle’s medium (DMEM) supplied with 10 %
(w/v) fetal bovine serum (FBS) at 37 °C in a humidified
incubator containing 5 % CO2. LPA was purchased from
Avantis Lipid (Alabaster, AL). DMEM, serum, and other
cell culture supplies were purchased from Maixin Bio-
technology (Fuzhou, China).
Clinical specimens
Clinical specimens were obtained from 52 primary epithe-
lial ovarian cancer patients and 15 non-tumor patients,
who underwent ovariectomy due to other diseases at the
Department of Obstetrics and Gynecology, Zhongnan
Hospital of Wuhan University, Wuhan, China, from
December, 2011 to December, 2015. All experiments were
approved by the Ethics Committee of Wuhan University.
The fresh specimens were frozen in liquid nitrogen and
stored at −80 °C. The formalin-fixed/paraffin-embedded
samples were also collected. Surgical pathological
stages were assessed according to the International Fed-
eration of Gynecology and Obstetrics (FIGO) criteria.
The range of carcinoma invasion and metastasis were
confirmed by surgical exploration and postoperative
pathological examination.
Matrigel invasion assay
The effect of LPA on cell invasion ability was measured
by Matrigel invasion assay (Corning Incorporated, MA,
USA). LPA dissolved in serum-free medium (20 μM)
was added into the underwells of invasion plates as a
chemoattractant to induce cell invasion, while the
serum-free medium without LPA was used as control.
Serum-starved ovarian cancer cells (105/well, in log
phase) were detached and plated into the upper
Matrigel-coated invasion chambers. The cells were then
allowed to invade for 48 h. The remaining cells in the
chambers were removed by cotton swabs and the
invaded cells on the lower surface of the chambers were
fixed and stained with crystal violet. Subsequently, the
crystal violet-stained cells were solubilized with 10 %
acetic acid and quantitated on a microplate reader at
600 nm. Fold increase in cell invasion was calculated to
evaluate the effects of LPAR1-3 silence on cells’ res-
ponsiveness for LPA(OD600 LPA-induced cell invasion
/OD600 base cell invasion).
Peritoneal metastatic colonization assay
Six-week-old athymic female homozygous nu/nu mice
were purchased from and cultured in the Animal Bio-
safety Level-3 Laboratory of Wuhan University under
sterile environment. Ovarian cancer cells in log-phase
were trypsinized, washed, and resuspended in PBS. The
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mice were intraperitoneally injected with different cell
lines (107 cells/mice), and monitored for five weeks. The
mice were then sacrificed and autopsied. Visible meta-
static implants were observed and photographed. All
animal experiment procedures were approved by the
Animal Center of Wuhan University.
RNA inference and overexpression
To test the role of LPARs in LPA-induced cell invasion,
specific shRNAs to LPAR1−3 were designed and intro-
duced into HEY and SK-OV3 cells. The shRNAs for each
target genes were designed with the aid of web-based Invi-
trogen Block-It program and inserted into pLV-shRNA
vector (Biosettia). The target sequences were as follows:
sh-LPAR1: 5’-GGATACCATGATGAGTCTTCT-3’, sh-LP
AR2: 5’-GCCTGGTCAAGACTGTTGTCA -3’, sh-LPAR3:
5’-GCCAAGGTGCAGTCTGCAATA-3’. Matrigel inva-
sion assay was performed in LPAR1-3 knockdown cell
lines, respectively. Vector containing coding sequence of
LPAR1 were got from Biochemistry and Molecular Biol-
ogy Department, Georgia Regents University, as a gift.
Lentiviral vector encoding LPAR1 were prepared by
subcloning the coding sequence into pCDH-CMV-MCS-
EF1-Puro vector. TOV21G and OVCAR3 cells were re-
spectively infected with lentiviral vectors encoding LPAR1
for 2 days and chosed by puromycin. The efficiency of
LPAR1 over-expression was tested by RT-PCT. After
2 days starvation, cells were stimulated with 20 μM LPA
and followed by the Matrigel invasion assay.
RNA isolation and qRT-PCR analysis
Total RNA was extracted with Trizol (Invitrogen,
Carlsbad, CA, USA) and treated by DNase I to remove
the remaining genomic DNA. The concentration of RNA
was determined at 260 nm and 280 nm by spectropho-
tometry, while the purity was detected by denaturing
agarose gel electrophoresis. DNase I-treated RNA (2 μg)
was reverse transcribed with SuperScriptase II. Generated
cDNA was subjected to real-time PCR to measure LPAR1,
LPAR2, LPAR3, and GAPDH levels with the respective
TaqMan probes and TaqMan@Universal PCR Master Mix
Kits (Applied Biosystems, Foster City, CA, USA). The
reaction was performed using ABI 9500Fast Real-time
machine and the conditions were as follows: 95 °C
for 10 min, followed by 40 cycles at 95 °C for 15 s
and 60 °C for 1 min. The expression levels of the tar-
get gene were standardized by comparing the Ct value
of target genes to the GAPDH, and presented as 2
[Ct(GAPDH) - Ct(target gene)] [21].
Immunohistochemistry
Paraffin-embedded sections (4 μm-thick) were deparaffi-
nized and rehydrated. Hydrogen peroxide treatment was
used to block endogenous peroxidase activity. Sections
were blocked with goat serum and incubated with poly-
clonal antibodies against LPAR1(Cat#: PAB10126),
LPAR2(Cat#: A-ALS10695) or LPAR3 (Cat#: A-AL
S10242). Primary antibodies were purchased from
Amyjet Scientific Inc. Antigens were visualized by
streptavidin-biotin-peroxidase complex method. Im-
munostaining was evaluated by two pathologists with-
out knowledge of patients’ clinical information. All
three antigens were found to be localized in cyto-
plasm. Extent of immunostaining was graded based
on the percentage of cells displaying staining. “-” is
considered as negative staining (<10); “+”, “++” and
“+++” were considered as positive staining (10-25 %,
25-50 % and >50 % respectively).
Statistical analysis
Statistical analyses of the invasion assay were performed
by ANOVA and independent t test. Chi-square test and
Fisher's exact test were used to compare covariates be-
tween LPARs expression and clinicopathological parame-
ters. All of the statistical tests were two-sided and P-values
of less than 0.05 were indicated as statistically significant.
Results
Effects of LPA on the migration of ovarian cancer cell
lines
To test whether the LPA response correlated with the
metastatic capability of ovarian cancer cells, we per-
formed LPA-induced invasion assay and peritoneal
metastatic colonization assay with a panel of established
human ovarian cancer cell lines. Invasion assay revealed
that not all the cell lines responded well to LPA. A sig-
nificant increase in cell invasion of ES2, OVCAR429,
HEY, OVCAR433, OVCAR5, SK-OV3, and OCC1 lines
was observed with LPA stimulation. However, the
OVCAR3, TOV21G, HEC1A, IGROV1, A2780, and
OVCAR4 cell lines showed poor or no response to LPA
with regard to cell invasion. Subsequently, the metastatic
potential of these cell lines was assessed by analyzing
metastatic colonization with a well established peritoneal
seeding model [22, 23]. Animals injected with ES2,
OVCAR429, HEY, OVCAR433, OVCAR5, SK-OV3, and
OCC1 lines (capable of responding to LPA for cell
migration) displayed overt metastatic implants on om-
entum, liver, and diaphragm, which resemble human
ovarian cancer; and these lines were designated as me-
tastatic. In contrast, metastatic colonization was not
observed in animals receiving OVCAR3, TOV21G,
HEC1A, IGROV1, A2780, and OVCAR4 (incapable of
responding to LPA for cell migration), and these lines
were referred to as non-metastatic (Fig. 1). These re-
sults, therefore, demonstrated that the LPA response
of ovarian cancer cells correlated well with their
metastatic potentials.
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Fig. 1 (See legend on next page.)
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LPAR mRNA expression in ovarian cancer cell lines
LPA-induced cellular events can be potentially medi-
ated by multiple LPA receptor subtypes [17, 18]. In the
present study, we focused on LPAR1-3 for their pos-
sible role in ovarian cancer cell invasion and metastasis,
as these are the most characterized lines and their aber-
rant expression have been detected in various cancer
tissues. The expressions of LPAR1-3 in different ovarian
cancer lines were examined by qRT-PCR. As shown in
Table 1, high expression levels of LPAR1 were revealed
in all the metastatic ovarian cancer cells (ES2,
OVCAR429, HEY, OVCAR433, OVCAR5, SK-OV3, and
OCC1). Furthermore, the t-test established that LPAR1
expression was significantly higher in metastatic cell
lines than in non-metastatic cell lines (P = 0.003). How-
ever, we also noticed that not all of the non-metastatic
cell lines were low level LPAR1 expressing ones.
OVCAR3, IGROV1 and TOV21G also expressed a
moderate level of LPAR1. On the contrary, we did not
detect any statistically significant difference in LPAR2
and LPAR3 transcript levels between metastatic lines
and non-metastatic lines. These results indicate the
possibility of LPAR1 as the key factor for ovarian
cancer cell metastasis.
LPAR1 is responsible for LPA-induced ovarian cancer cell
invasion
Specific shRNAs targeting LPAR1-3 were designed
and introduced into HEY and SK-OV3 cells. The
efficiency of target gene knockdown was confirmed
by qRT-PCR (Fig. 2). Silencing LPAR1 alone signifi-
cantly reduced LPA-induced cell invasion (P < 0.001).
On the contrary, LPAR2-shRNA displayed slight and
LPAR3-shRNA exhibited no effect on LPA-induced cell
invasion (P = 0.193, P = 0.248 respectively). These results
indicated that LPA-stimulated ovarian cancer cell in-
vasion was mediated mainly through LPAR1. Our data
above also showed some cell lines with moderate
LPAR1 expression were non-metastatic ovarian cells.
To rule out the possibility that LPA non-responsive
lines contained potential function-impairing mutation
in LPAR1 sequence, we lentivirally transduced LPAR1
into IGROV1, TOV21G and OVCAR3 lines. However,
these lines with LPAR1 overexpression remained non-
responsive to LPA for cell invasion. These results
indicate that the inability of LPA to stimulate cell inva-
sion in LPA non-responsive line is not at the step of
LPA receptors.
(See figure on previous page.)
Fig. 1 Correlation between response to LPA-induced invasion and metastatic colonization potential of ovarian cancer cells. a Invasion of ovarian
cancer cells stimulated by LPA. Cell invasion was measured using Matrigel invasion assay with/without 20 μM LPA in the underwells. Peritoneal
metastatic colonization assay. The nu/nu mice were intraperitoneally injected with different cell lines (107cells/mice), and autopsied five weeks
later. Visible metastatic implants were observed and photographed. b The invaded cells were stained with crystal violet, dissolved in 10 % acetic
acid and quantitated with a microplate reader at 600 nm. All samples were performed in triplicate. Data are expressed as the means ± SE
Table 1 Expression levels of the three LPARs in ovarian cancer cell lines
LPAR1 LPAR2 LPAR3
mRNA expression P value mRNA expression P value mRNA expression P value
Invasive ovarian cancer cells
ES2 1.591 ± 0.033 0.075 ± 0.031 0.702 ± 0.047
OVCAR429 2.235 ± 0.014 1.602 ± 0.012 0.086 ± 0.071
HEY 0.770 ± 0.038 0.005 ± 0.063 0.261 ± 0.032
OVCAR433 1.919 ± 0.013 0.847 ± 0.085 0.064 ± 0.044
OVCAR5 0.715 ± 0.012 0.140 ± 0.033 0.005 ± 0.017
SKOV3 0.633 ± 0.078 0.087 ± 0.087 0.177 ± 0.105
OCC1 1.165 ± 0.014 0.138 ± 0.011 2.751 ± 0.037
Non-invasive ovarian cancer cells 0.003* 0.246 0.804
OVCAR3 0.252 ± 0.011 0.192 ± 0.021 0.451 ± 0.022
HEC1A 0.002 ± 0.025 0.053 ± 0.045 0.001 ± 0.065
IGROV1 0.383 ± 0.045 0.129 ± 0.015 0.082 ± 0.045
TOV21G 0.274 ± 0.024 0.002 ± 0.024 0.026 ± 0.008
A2780 0.007 ± 0.014 0.081 ± 0.033 2.070 ± 0.102
OVCAR4 0.001 ± 0.013 0.268 ± 0.008 0.067 ± 0.073
* P < 0.003 indicates statistically significant difference
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LPAR protein expression in clinical specimens
As laboratory studies may not recapitulate clinical ovar-
ian malignancy, we extended our study by detecting
LPARs expression in fresh specimens from patients by
qRT-PCR and immunohistochemistry (Additional file 1:
Table S1). The qRT-PCR results showed that LPAR1,
LPAR2, and LPAR3 were positive in 75.00 %, 12.50 %,
and 6.25 % in the 15 of the normal ovarian specimens,
respectively; and 69.23 %, 42.31 %, 17.31 % in the 52 of
the ovarian cancer specimens, respectively. The expres-
sion rate of LPAR2 was much higher in ovarian cancer
specimens than in normal ones (P = 0.039). LPAR3
expression rate is also increased in cancer than in nor-
mal specimens, though the difference is not statistically
significant (P = 0.275). On the contrary, no significant
difference in LPAR1 expression between normal or can-
cer specimens were observed (P = 0.658). To further
evaluate the role of LPARs in ovarian cancer metastasis,
we analyzed the relationships between the expression of
LPARs and clinicopathological features. As presented in
Table 2, LPAR1 expression rate increased significantly
with more advanced clinical stages (stage I: 16.67 %; II
50.00 %; III: 75.00 %; and IV: 100.00 %; P = 0.003). Besides,
LPAR1 expression was detected in all the 13 cases with
abdominal metastasis, more than 2 cm; 16 cases with
retroperitoneal lymph node metastasis; and 6 cases with
hepatic metastasis. We also found that LPAR2 and LPAR3
expression rate increased along with the more advanced
pathologic grades (P = 0.002, P = 0.034, respectively). The
immunohistochemistry also demonstrated that LPAR1
positive percentage increased along with the clinical stages
(stage I: 15.38 %; II 37.50 %; III: 66.67 %; and IV: 83.33 %;
P = 0.002), while LPAR2 and LPAR3 positive percentage
increased along with the pathologic grades (P = 0.005,
P = 0.025, respectively) (Fig. 3). These results were in
accordance with the data from RT-PCR.
Fig. 2 Effects of silencing LPA1-3 on ovarian cancer cells’ response for LPA-induced invasion. a SK-OV3 and HEY cells were transduced with
control or LPAR1-3 shRNAs and then analyzed for cell invasion with or without 20 μM LPA contained in the underwells. Results are presented as
fold increase of cell invasion (OD600 LPA-induced cell invasion /OD600 base cell invasion). Data are means SE. n = 3. Differences between groups
were assessed using Student t test. b We lentivirally overexpressed LPAR1 in I IGROV1, TOV21G and OVCAR3 lines. Enforced LPAR1 expression was
unable to render non-metastatic IGROV1, TOV21G and OVCAR3 cells responding to LPA for cell invasion
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Discussion
LPA is present at high concentrations in the ascites in
patients with ovarian cancer. A number of experimental
studies have demonstrated that LPA can promote ovar-
ian cancer cell proliferation/survival, and induce the
production of proangiogenic factors [14, 15] and prote-
ases [11, 12]. In this study, LPA was shown to be a
potent invasion stimulator for various ovarian cancer cell
lines. These findings suggested a possibility of the involve-
ment of peritoneal fluid or ascites-contained LPA in
spreading and disseminating ovarian cancer cells. As cell
invasion is one of the most crucial components of cancer
metastasis, we reasoned that the ability of ovarian cancer
cells to respond to LPA for cell invasion may be essential
for their peritoneal metastasis. This theory was further
supported by the observation that LPA-stimulated cell
Table 2 Relationship between clinical characteristics of ovarian cancer patients and the expression of LPAR1-3
Total (N) LPAR1-Positive (%) P value LPAR2- Positive (%) P value LPAR3-Positive (%) P value
52 36 (69.23) 22 (42.31) 9 (17.31)
Histological subtypes 0 0.664 0.587 0.542
Serous 26 20 (76.925) 11 (42.31) 4 (15.38)
Mucinous 8 5 (62.5 %) 3 (37.50) 2 (25.00)
Endometroid 12 7 (58.33 %) 4 (33.33) 3 (25.00)
Clear cell/Undifferentiated 6 4 (66.67 %) 4 (66.67) 0 (0)
Differentiation 0.415 0.002* 0.034*
High 13 10 (76.92) 2 (15.38) 2 (15.38)
Moderate 20 12 (60.00) 6 (30.00) 2 (10.00)
Poor 19 14 (73.68) 14 (73.68) 5 (26.32)
Clinical stage 0.003* 0.712 0.678
FIGO I 6 1 (16.67) 3 (50.00) 2 (33.33)
FIGO II 8 4 (50.00) 3 (37.5) 2 (25.00)
FIGO III 28 21 (75.00) 12 (42.86) 4 (14.29)
FIGO IV 10 10 (100.00) 4 (40.00) 1 (10.00)
* P <0.05 indicates statistically significant difference
Fig. 3 Immunohistochemistry of LPAR, LPAR2 and LPAR3 on ovarian cancer specimens. (×100)
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invasion presented an excellent correlation with peritoneal
metastatic colonization of ovarian cancer cells.
LPA mediates various biological responses through its
interaction with LPA receptors, namely LPAR1, LPAR2,
and LPAR3, which belong to the G protein-coupled
receptor (GPCR) superfamily. By binding to LPARs, LPA
can activate three distinct G-protein subfamilies (G12/13,
Gi and Gq), and then stimulate multiple downstream
signaling pathways including Ras-MAPK, Rho GTPase,
and KT/PKB. Eventually, it can trigger a series of bio-
logical events [24]. Most of the previous studies about
LPA-induced ovarian cancer metastasis have emphasized
on the downstream regulatory factors. Rare reports
systematically studied the correlation between LPA
receptors and ovarian cancer metastasis, and the role of
LPARs in cancer metastasis is still under controversial.
Park et al. reported an elevation in the expression levels
of LPAR1 and matrix metalloproteinase (MMP)-9 due to
LPA, which subsequently induced hepatocellular carcin-
oma (HCC) cell invasion [25]. Mayumi Komachi’ study
indicated that LPA1 receptors mediate stimulation,
whereas LPA2 receptors mediate inhibition, of migration
of pancreatic cancer cells in response to lysophosphati-
dic acid and malignant ascites [26]. Chen et al. suggested
that LPAR2 (EDG4) and LPAR1 (EDG2) could coopera-
tively promote an efficient Rho-dependent chemotaxis in
breast carcinoma cells, while they observed LPA2 to be
less efficacious [27]. In a similar study, Yu et al. found
that the expression of LPA2 and LPA3 mRNAs were
higher in most ovarian cancer cell lines as compared
with normal ovarian epithelial cells. However, in our
study, we demonstrated that LPAR1 expression in inva-
sive ovarian cancer cells was significantly higher than in
non-invasive ones; while the expression of LPAR2 and
LPAR3 had no statistical correlation with the metastatic
potential of ovarian cancer cells. This difference may be
attributed to differences in the cell lineage. Moreover,
we observed that LPAR1 was highly expressed in all
invasive ovarian cancer cells and all the three low LPAR1
expressing cells are non-invasive ones through there are
still three of non-invasive lines expressing a moderate level
of LPAR1. Besides that, silencing LPAR1 alone could sig-
nificantly reduce LPA-induced invasion. Our in vitro data
suggested that LPAR1 is the major receptor of LPA-
induced ovarian cancer metastasis. As multiple signaling
pathways are involved in tumor cell migration, there may
also be other key factors in signal transmission of ovarian
cancer besides LPAR1. Lack of certain downstream factors
may lead to the depression of tumor cell invasion. This
may explain why LPAR1 overexpression could not render
IGROV1, TOV21G and OVCAR3 lines capable of
responding to LPA for invasion in our study.
LPA receptors are widely distributed in embryos,
tissues, and cell lines, and each subtype has a distinct
specificity. Recent studies have evaluated the expression
of LPA receptors in clinical specimens. For instance,
Shida et al. observed a reduced expression of LPAR1 and
increased expression of LPAR2 in colorectal cancers as
compared with normal mucosa. The ratio of LPA2/LPA1
in cancer tissues contributes to pathogenesis in cancer
biology [28]. The expression levels of LPA receptors in
human epithelial ovarian neoplasms were detected using
RT-PCR by Wang et al., and LPAR2 and LPAR3 were
found to be overexpressed in ovarian cancer when
compared with tissues from normal ovaries and benign
ovarian tumors [29]. In our study, we also found that the
expression rate of LPAR2 increased in ovarian cancer
than in normal specimens. LPAR3 expression showed
the same trend as LPAR2, though the difference is not
statistically significant. Besides that LPAR2 and LPAR3
expression increased along with poorer differentiation.
These data suggested that LPAR2 and LPAR3 might play
an role in carcinogenesis but not in cancer cell invasion.
On the contrary, the expression of LPAR1 did not show
any difference between cancer and normal tissues;
however, it was observed to increase with more ad-
vanced clinical stages. The expression of LPAR1 was
further revealed in cases with abdominal metastasis
(greater than 2 cm), retroperitoneal lymph node me-
tastasis, and hepatic metastasis. This observation corrob-
orated the results generated from the cell lines that
LPAR1 is the main receptor responsible for the LPA-
induced ovarian cancer metastasis.
Conclusions
In summary, our study demonstrated that LPA response
might be a prerequisite for peritoneal metastasis of ovar-
ian cancer cells, and that LPAR1 is the major mediator
for LPA-induced ovarian cancer invasion as well as me-
tastasis. Although our results were supported with estab-
lished ovarian cancer cell lines, which may not
completely simulate the clinical settings, the consistency
seen in multiple cell lines, the convergence of loss- and
gain-of-function findings, and especially, the significant
correlation observed between LPAR1 expression and ad-
vanced disease stage/wider spreading range strongly
argue against any confounding influence derived from
our experimental studies. As LPA receptors are located
on the cell surface and easily influenced by drugs, there
lies immense potential in developing a therapeutic ap-
proach by targeting LPAR1 and its downstream factors.
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